COPANLISIB AND VOLASERTIB OVERCOME IBRUTINIB‐VENETOCLAX RESISTANCE VIA TARGETING PI3K‐AKT SIGNALING AND G2/M CELL CYCLE TRANSITION IN MANTLE CELL LYMPHOMA. (12th June 2019)